Document is current
Any future updates will be listed below
-
Authors
Jansa, Pavel
Pulido, Tomás
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct00660179 at ClinicalTrials.govDocuments that mention this clinical trial
P17 Pharmacokinetics of macitentan in patients with portopulmonary hypertension: findings from the PORTICO sub-study
https://doi.org/10.1136/thorax-2018-212555.175
Adjusting Overall Survival Estimates of Macitentan in Pulmonary Arterial Hypertension After Treatment Switching: Results from the SERAPHIN Study
https://doi.org/10.1007/s12325-022-02253-8
Macitentan in Pulmonary Arterial Hypertension: A Focus on Combination Therapy in the SERAPHIN Trial
https://doi.org/10.1007/s40256-017-0260-1
-
Funding
Funding for this research was provided by:
Actelion Pharmaceuticals
- License Information
-
More Information
Article History
First Online: 26 December 2017
Compliance with Ethical Standards
:
: Pavel Jansa has received fees and grants from Actelion Pharmaceuticals Ltd, United Therapeutics, AOP Orphan, Bayer HealthCare, MSD, and GlaxoSmithKline. He has served on advisory boards for Actelion Pharmaceuticals Ltd, Bayer HealthCare, and MSD. Tomás Pulido’s institution has received research grants from Actelion Pharmaceuticals Ltd, United Therapeutics, GlaxoSmithKline, Bayer HealthCare, and Reata Pharmaceuticals. He has served as a consultant and received honoraria for lectures from Actelion Pharmaceuticals Ltd, Bayer HealthCare, and GlaxoSmithKline. He has participated as a principal investigator in trials sponsored by Actelion Pharmaceuticals Ltd.
